Clinical Application of CTDNA in Operable Breast Cancer Patients

Inclusion Criteria

• •1. Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures.
• •2. Age of at least 18 and at most 70 years.
• •3. Performance status (Karnofsky-Index) \>80%.
• •4. Chemotherapy is necessary before or after surgery.
• •5. No clinical evidence of local recurrence or distant metastases.
• •6. Complete staging work-up within 3 months prior to registration. All patients must have (bilateral) mammography or breast MRI, chest X-ray; other tests may be performed as clinically indicated.
• •7. Life expectancy of at least 2 years, disregarding the diagnosis of cancer.
• •8. Adequate organ function including normal red and white blood count, platelets, serum creatinine, bilirubin, and transaminases within normal range of the institution.
• •9. Patients must be available for and compliant to treatment and follow-up.
• •10. Patients registered on this trial must be treated and followed up at the participating center.